Multi-Cancer
Oncomine Precision Assay
50 genes
DNA & RNA inputs
SNVs/Indels
CNVs
Fusions
The number of molecular biomarkers relevant for precision oncology research is rapidly growing across solid tumors, and in many cases, sequential single-gene testing methods do not yield desired results in time or for only a limited number of biomarkers.
Therefore, next-generation sequencing (NGS) has become a technology of choice in precision oncology research for genomic profiling from formalin-fixed paraffin-embedded (FFPE) tissue or liquid biopsy samples*.
 Oncomine Precision Assay 50 Genes |
Oncomine Comprehensive Assay V3 161 Genes |
|
|
|
Rapid detection of relevant biomarkers for NSCLC, melanoma, colon, thyroid, and cholangiocarcinoma and majority of biomarkers relevant in other tumor types. | Rapid detection of relevant biomarkers for majority of solid tumors including breast and prostate cancer. HRR genes, tumor suppressor genes such as POLE & MDM amongst others. |
Comprehensive genomic profiling (CGP) including relevant biomarkers for the majority of solid tumors including ovarian cancer, and gene signatures including, homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI). |
|
Turnaround time (TAT) as little as 24 hours. | Turnaround time (TAT) as little as 26 hours. | Turnaround time (TAT) in 3 days. |
|
10 ngs of DNA/RNA enabling more cancer research samples to be profiled. | 20 ngs of DNA/RNA enabling more cancer samples to be profiled. | 20 ngs of DNA/RNA enabling more cancer samples to be profiled. |
Oncomine™ assays cover biomarkers across multiple solid tumors and enable labs to choose the most efficient tool
for each tumor sample.
A diverse menu of targeted assays with multi-cancer and tumor type-specific coverage to fit your clinical research needs.
Explore Oncomine Liquid Biopsy NGS Solutions
Oncomine Precision Assay
50 genes
DNA & RNA inputs
SNVs/Indels
CNVs
Fusions
Oncomine Pan-Cancer Cell-Free Assay
52 genes
DNA & RNA inputs
SNVs/Indels
Full-length APC, FBXW7,
PTEN,TP53
CNVs
Fusions
Oncomine Lung cfTNA Assay
12 genes
DNA & RNA inputs
SNVs/Indels
CNVs
Fusions
Oncomine Breast cfDNA Assay v2
12 genes
SNVs/Indels
CNVs
TP53
Oncomine Colon cfDNA Assay
14 genes
SNVs/Indels
Cancer research is increasingly focused on precision oncology approaches that rely on the detection of biomarkers.
Deeper knowledge of molecular pathways, their interactions, and fundamental understanding of cancer biology may elucidate the progression and help predict the response of future treatments.
Oncomine Solutions provide highly automated end-to-end workflows which enable oncology biomarkers detection in a broad spectrum of laboratories.
Download our Biomarker Guides and Learn about emerging biomarker testing.
Request to speak to a Thermo Fisher Scientific NGS expert below. We will be happy to answer all your question and provide a demo.
